Bayer Pharma Head Sees Brighter Future With Deals, New Drugs (2)

Bayer AGis considering doing deals in the range of €1 billion to €5 billion ($1.1 billion to $5.5 billion) as the drugmaker seeks to rebuild its pipeline of new medicines.

Top drugs are losing exclusivity and a promising experimental candidate recently failed. But Bayer’s pharma head, Stefan Oelrich, said Monday that the company has built up a portfolio of earlier-stage assets that show a lot of promise, and he’s also open to licensing deals for existing drugs.

“If we buy new things, there are ways to create some space in terms of capital allocation,” Oelrich said in an ...